Hirak Der Torossian MD Mph
About Hirak Der Torossian MD Mph
Hirak Der Torossian, MD, MPH, serves as the Executive Medical Director at Mirati Therapeutics, a position he has held since 2021. He has extensive experience in clinical research and medical leadership, with previous roles at the University of Vermont and various positions at Mirati Therapeutics.
Work at Mirati Therapeutics
Hirak Der Torossian currently serves as the Executive Medical Director at Mirati Therapeutics, a position he has held since 2021. Prior to this role, he worked at Mirati Therapeutics as Medical Director from 2015 to 2019 and then as Senior Medical Director from 2019 to 2021. His tenure at Mirati Therapeutics spans a total of six years, during which he has contributed to the company's focus on developing targeted therapies for cancer treatment.
Education and Expertise
Hirak Der Torossian holds a Master of Public Health (MPH) from The Johns Hopkins University, which he completed from 2008 to 2009. He also earned a Doctor of Medicine (MD) degree from the American University of Beirut, studying there from 2003 to 2007. Additionally, he obtained a Bachelor of Science (BS) in Biology from the same institution, graduating in 2003. His educational background provides a strong foundation in both medicine and public health.
Background
Before joining Mirati Therapeutics, Hirak Der Torossian held various positions at the University of Vermont. He served as Clinical Research Director in the Department of Surgery from 2013 to 2015 and as H&N Cancer Research Manager and J Walter Juckett Postdoctoral Fellow from 2010 to 2013. He also worked as Adjunct Faculty in the Department of Surgery from 2011 to 2014. Earlier in his career, he completed a postdoctoral fellowship at the University of Pittsburgh Medical Center from 2009 to 2010.
Professional Experience
Hirak Der Torossian has extensive experience in the medical field, particularly in cancer research and clinical practice. His roles at Mirati Therapeutics and the University of Vermont have involved significant responsibilities in clinical research and medical direction. His work has focused on advancing therapeutic strategies and improving patient outcomes in oncology.